BackAvalo Therapeutics Overview

Avalo Therapeutics Research & Development

Research & Development expenses for AVTX.

Quarterly R&D Expenses

$14.05M
53.97% YoY

As of Mar 31, 2026

Annual R&D Expenses (TTM)

$55.01M
74.94% YoY

Trailing 12 months ending Mar 31, 2026

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)